Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.
Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.
复制标题
DOI：
10.1038/s41467-021-25479-6
复制
发表时间：
2021-08-26
影响因子：
16.6
通讯作者：
Tafesse FG
中科院分区：
文献类型：
--
作者：
Bates TA;Leier HC;Lyski ZL;McBride SK;Coulter FJ;Weinstein JB;Goodman JR;Lu Z;Siegel SAR;Sullivan P;Strnad M;Brunton AE;Lee DX;Adey AC;Bimber BN;O'Roak BJ;Curlin ME;Messer WB;Tafesse FG
尽管推出了有效的疫苗，但 SARS-CoV-2 及其变种每天仍继续感染数十万人。因此，了解这些疫苗在面对新出现的变种时提供的保护水平至关重要。在这里，我们报告了两个人口统计平衡的 BNT162b2 疫苗接种者和 COVID-19 患者队列，从中我们评估了针对 SARS-CoV-2 以及 B.1.1.7（α）和 B.1.351（β）变体的中和抗体滴度。我们表明，B.1.1.7 和 B.1.351 都不太容易被来自接种疫苗的个体的血清中和，并且 B.1.351（而不是 B.1.1.7）不太容易被恢复期血清中和。我们还发现变体特异性抗刺突抗体的水平与中和活性成正比。总之，我们的结果表明，新出现的 SARS-CoV-2 变体逃脱了血清抗体的中和作用，这可能导致对再次感染的保护作用减弱或疫苗突破的风险增加。在这里，作者表明，中和来自 BNT162b2 疫苗接种者和恢复期 COVID-19 患者的人血清对 SARS-CoV-2 变种 B.1.1.7 和 B.1.351 的效率较低，并且与患者年龄呈负相关。
SARS-CoV-2 and its variants continue to infect hundreds of thousands every day despite the rollout of effective vaccines. Therefore, it is essential to understand the levels of protection that these vaccines provide in the face of emerging variants. Here, we report two demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we evaluate neutralizing antibody titers against SARS-CoV-2 as well as the B.1.1.7 (alpha) and B.1.351 (beta) variants. We show that both B.1.1.7 and B.1.351 are less well neutralized by serum from vaccinated individuals, and that B.1.351, but not B.1.1.7, is less well neutralized by convalescent serum. We also find that the levels of variant-specific anti-spike antibodies are proportional to neutralizing activities. Together, our results demonstrate the escape of the emerging SARS-CoV-2 variants from neutralization by serum antibodies, which may lead to reduced protection from re-infection or increased risk of vaccine breakthrough. Here, the authors show that neutralization of human sera from both BNT162b2 vaccine recipients and from convalescent COVID-19 patients is less efficient against SARS- CoV-2 variants B.1.1.7 and B.1.351 and negatively associated with patient age.
登录
查看更多内容
影响因子：
48
作者：
Vitak SA;Torkenczy KA;Rosenkrantz JL;Fields AJ;Christiansen L;Wong MH;Carbone L;Steemers FJ;Adey A
通讯作者：
Adey A
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
DOI：
10.1016/s0140-6736(21)00183-5
发表时间：
2021-02-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Sabino EC;Buss LF;Carvalho MPS;Prete CA Jr;Crispim MAE;Fraiji NA;Pereira RHM;Parag KV;da Silva Peixoto P;Kraemer MUG;Oikawa MK;Salomon T;Cucunuba ZM;Castro MC;de Souza Santos AA;Nascimento VH;Pereira HS;Ferguson NM;Pybus OG;Kucharski A;Busch MP;Dye C;Faria NR
通讯作者：
Faria NR
影响因子：
64.8
作者：
Plante JA;Liu Y;Liu J;Xia H;Johnson BA;Lokugamage KG;Zhang X;Muruato AE;Zou J;Fontes-Garfias CR;Mirchandani D;Scharton D;Bilello JP;Ku Z;An Z;Kalveram B;Freiberg AN;Menachery VD;Xie X;Plante KS;Weaver SC;Shi PY
通讯作者：
Shi PY
影响因子：
13.8
作者：
Rosenthal N;Cao Z;Gundrum J;Sianis J;Safo S
通讯作者：
Safo S